Deferiprone treats iron overload in certain patients. Can cause reddish/brown urine. It should be taken at least 4 hours apart from other medications such as aluminum containing antacids.

Deferiprone Overview


Deferiprone is a prescription medication used to treat an overload of iron in the body. Deferiprone belongs to a group of drugs called iron chelators. These work by attaching to iron so that it can be removed from the body. 

This medication comes as an oral (by mouth) tablet and is usually taken 3 times a day. Deferiprone may be taken with or without food. Taking it with food may help with nausea that may be caused by deferiprone.

Common side effects of deferiprone include reddish-brown urine, nausea, vomiting, and stomach pain.

How was your experience with Deferiprone?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Deferiprone?

What are you taking Deferiprone for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Deferiprone work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Deferiprone to a friend?

Deferiprone Cautionary Labels


Uses of Deferiprone

Deferiprone is a prescription medication used to treat an overload of iron in the body in people who have had a large number of blood transfusions due to a condition called thalessemia. Thalessemia is an inherited blood disorder that causes decreased numbers of red blood cells. Deferiprone should only be used when other treatments for removal of excess iron have not worked.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Deferiprone Brand Names

Deferiprone may be found in some form under the following brand names:

Deferiprone Drug Class

Deferiprone is part of the drug class:

Deferiprone FDA Warning

Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.

Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor the ANC weekly on therapy. Interrupt deferiprone therapy if neutropenia develops.

Interrupt deferiprone if infection develops, and monitor the ANC more frequently.

Advise patients taking deferiprone to report immediately any symptoms indicative of infection.